Mechanism of Action
Synergistic Membrane Disruption with Magainin
PGLa alone adopts a surface-lying helix orientation on lipid bilayers. Magainin-2 alone transiently inserts as toroidal pores. Together, PGLa and magainin-2 form stable, long-lived pores that cannot be formed by either peptide independently. Solid-state NMR studies show that in the complex, PGLa reorients from surface-bound to transmembrane orientation, stabilized by magainin-2 contacts. This cooperative pore formation is a unique mechanism distinct from single-peptide AMP action.
Lipid Selectivity
PGLa selectivity for bacteria over mammalian cells parallels magainin, driven by electrostatic preference for anionic lipids (PG, CL) enriched in bacterial membranes. The synergistic combination with magainin dramatically lowers the effective concentration needed, improving the therapeutic window by moving the active concentration further below the hemolytic threshold for each peptide.
Research Summary
Synergy Characterization
PreclinicalThe PGLa-magainin synergy has been studied extensively by NMR, electron microscopy, dye-leakage assays, and molecular dynamics simulation. The 1:1 molar ratio is optimal for maximal synergy. FIC (fractional inhibitory concentration) indices of 0.01-0.03 have been reported, indicating strong synergistic killing. This synergy validates the design principle of combining mechanistically complementary AMPs for enhanced activity.
Analog Development
PreclinicalModified PGLa analogs with enhanced hydrophobicity or charge optimization show improved individual potency but often lose the synergistic partnership with magainin. Studies mapping the structural requirements for synergy have identified key residues in both peptides that mediate the cooperative interaction. This knowledge guides the design of new synergistic AMP pairs from different scaffolds.
Calculate your PGLa dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Antimicrobial alone (in vitro) | 10-50 uM MIC | Single exposure | Direct application |
| PGLa + Magainin synergy | 0.1-1 uM (combined) | Single exposure | Direct application |
Synergistic combination achieves activity at 1-2% of individual MIC values.
Interactions
Safety Profile
PGLa shows low hemolytic activity alone. The synergistic combination with magainin is effective at concentrations well below those causing hemolysis. Proteolytic instability limits systemic use. No human clinical data. The synergy principle has been applied in pexiganan development.
References
- [1]Westerhoff HV, et al. (1995). Functional synergy of the magainin peptides and the cecropins with each other and with classical antibiotics. J Antimicrob Chemother, 21 Suppl A, 163-174.
- [2]Tremouilhac P, et al. (2006). Conditions affecting the re-alignment of the antimicrobial peptide PGLa in membranes as monitored by solid state 2H NMR. Biochim Biophys Acta, 1758(9), 1330-1342.